Orion Oyj : Orion invites analysts and media to Financial Statement Release conference on Tuesday 5 February 2013

 Orion Oyj : Orion invites analysts and media to Financial Statement Release
                    conference on Tuesday 5 February 2013


Orion will publish its Financial Statement Release for 2012 on Tuesday, 5
February 2013 approximatelyat 12:00 Finnish time (EET). The release and
related presentation material in Finnish and in English will be available on
the Group's homepage at www.orion.fi/en/investors promptly after the

  News conference for analysts and media on Tuesday 5 February 2013 at 13:30

A news conference for analysts and media will be held on Tuesday 5 February
2013 at 13:30 EET atHotel Kämp, address Pohjoisesplanadi 29, Helsinki.
President and CEO Timo Lappalainen will give a brief presentation in English
on the financial review.

  Live webcast and conference call

The event can be followed live as a webcast accessible at

Questions can be asked also through conference call lines after the result

The conference call ID is 927 747 and the phone numbers to participate the
conference are:
when calling from the United States +1 866 803 8344
when calling from other countries +44 (0)20 7162 0125

  News conference recordings

A recording of the event in English and a recording of the presentation by the
President and CEO in Finnish will be available on the Orion website later the
same day.

  Silent period

The silent period preceding the publication is ongoing and continues until the

Orion Corporation

Timo Lappalainen  Jari Karlson
President and CEO CFO

Orion Corporation
Orionintie 1A, FI-02200 Espoo

Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical
ingredients and diagnostic tests. The company is continuously developing new
drugs and treatment methods. Pharmaceutical R&D focuses on central nervous
system drugs, oncology and critical care drugs, and Easyhaler^® pulmonary

Orion's net sales in 2011 amounted to EUR 918 million and the company had
about 3,400 employees. Orion's A and B shares are listed on NASDAQ OMX


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Orion Oyj via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.